Physician profile
John P Morrow
NPI 1679730428
$5,960.80
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $157 · 2021: $127 · 2022: $1,114 · 2023: $1,252 · 2024: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194 · Travel and Lodging: $245 · Grant: $58.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.32 |
| Travel and Lodging | $244.64 |
| Grant | $58.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,005.12 | 2019-2024 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, S-Icd System Magnet |
| Biotronik INC. | $1,875.88 | 2023-2024 | Acticor 7 Vr-T Dx, Amvia Edge, Rivacor 7 Dr-T |
| Abbott Laboratories | $691.47 | 2019-2024 | Aveir, Gallant, Jot Dx |
| Biosense Webster, INC. | $663.72 | 2019-2024 | Carto 3, Octaray Mapping Catheter, Nuvision Ice Catheter |
| Medtronic Vascular, INC. | $282.24 | 2019-2020 | |
| Medtronic, INC. | $261.19 | 2022 | |
| Impulse Dynamics (USA) INC. | $139.83 | 2024 | Optimizer |
| Astellas Pharma US INC | $24.87 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.